GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (FRA:3371) » Definitions » Net Interest Income (for Banks)

Corbus Pharmaceuticals Holdings (FRA:3371) Net Interest Income (for Banks)


View and export this data going back to 2016. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Corbus Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.